Novel Compounds as TEAD Inhibitors for Treating Cancer
- PMID: 37736181
- PMCID: PMC10510495
- DOI: 10.1021/acsmedchemlett.3c00346
Novel Compounds as TEAD Inhibitors for Treating Cancer
Abstract
Provided herein are novel compounds as TEAD inhibitors, pharmaceutical compositions, use of such compounds in treating cancer, and processes for preparing such compounds.
Published 2023 by American Chemical Society.
Conflict of interest statement
The author declares no competing financial interest.
Similar articles
-
Novel Indazole Compounds as TEAD Inhibitors for Treating Cancer.ACS Med Chem Lett. 2023 Sep 20;14(10):1334-1335. doi: 10.1021/acsmedchemlett.3c00392. eCollection 2023 Oct 12. ACS Med Chem Lett. 2023. PMID: 37849539 Free PMC article.
-
Novel Heteroaryl Compounds as CD73 Inhibitors for Treating Cancer.ACS Med Chem Lett. 2024 May 31;15(6):775-776. doi: 10.1021/acsmedchemlett.4c00230. eCollection 2024 Jun 13. ACS Med Chem Lett. 2024. PMID: 38894910
-
Novel 2,7-Naphthyridine Compounds as MASTL Inhibitors for Treating Cancer.ACS Med Chem Lett. 2024 May 1;15(6):748-749. doi: 10.1021/acsmedchemlett.4c00177. eCollection 2024 Jun 13. ACS Med Chem Lett. 2024. PMID: 38894901
-
Novel Pyrazoloquinoline Compounds as KRAS Inhibitors for Treating Cancer.ACS Med Chem Lett. 2023 Jul 25;14(8):1045-1046. doi: 10.1021/acsmedchemlett.3c00300. eCollection 2023 Aug 10. ACS Med Chem Lett. 2023. PMID: 37583830 Free PMC article.
-
A chemical perspective on the modulation of TEAD transcriptional activities: Recent progress, challenges, and opportunities.Eur J Med Chem. 2022 Dec 5;243:114684. doi: 10.1016/j.ejmech.2022.114684. Epub 2022 Aug 30. Eur J Med Chem. 2022. PMID: 36063664 Review.
Cited by
-
Novel Indazole Compounds as TEAD Inhibitors for Treating Cancer.ACS Med Chem Lett. 2023 Sep 20;14(10):1334-1335. doi: 10.1021/acsmedchemlett.3c00392. eCollection 2023 Oct 12. ACS Med Chem Lett. 2023. PMID: 37849539 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources